SequelSEC

Minerva Neurosciences, Inc. NERV

Pharmaceutical Preparations · CIK 0001598646 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2021-12-31
Operating income
-$45.37M
Fiscal year ended 2021-12-31
Free cash flow
Unavailable
Fiscal year ended 2021-12-31

Minerva Neurosciences, Inc. (NERV) reported revenue of $0 and net income of -$49.91M for the fiscal year ended 2021-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Minerva Neurosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Minerva Neurosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-31
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$45.37M
Net income-$49.91M
Research & development$32.04M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$13.33M
Selling & marketingUnavailable

Balance

Minerva Neurosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-31
Cash & equivalents$60.76M
Total assets$77.12M
Current assets$62.20M
Total liabilities$69.15M
Current liabilities$2.82M
Total equity incl. NCI$7.98M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
Goodwill$14.87M
Long-term debtUnavailable
Accounts payable$1.85M

Cash flow

Minerva Neurosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-31
Operating cash flow-$24.60M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$60.00M
Net change in cash$35.40M
Stock-based compensation$5.22M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Minerva Neurosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-31
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio22.07x
Revenue YoY growth-100.0%
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NERV in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-11View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.